Suchergebnisse - "Kashiwaba, Masahiro"

PubPharm (110)

1

Long-term prognostic value of the GenesWell BCT score in Asian women with hormone receptor-positive/HER2-negative early breast cancer

enthalten in: Breast cancer (Tokyo, Japan) | 2024

von Fujiki, Y. | Kashiwaba, M. | Sato, M. | +14

2

Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy

enthalten in: Breast cancer research and treatment | 2023

von Iwata, H. | Yamamoto, Y. | Sakai, T. | +12

3

Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy

enthalten in: Breast cancer research and treatment | 2023

von Iwata, H. | Yamamoto, Y. | Sakai, T. | +12

4

Adjuvant trastuzumab without chemotherapy for treating early HER2-positive breast cancer in older patients : A propensity score-adjusted analysis of a prospective cohort study

enthalten in: Breast (Edinburgh, Scotland) | 2022

von Sawaki, M. | Taira, N. | Uemura, Y. | +20

5

Pertuzumab retreatment for HER2-positive advanced breast cancer : A randomized, open-label phase III study (PRECIOUS)

enthalten in: Cancer science | 2022

von Yamamoto, Y. | Iwata, H. | Taira, N. | +19

6

Adjuvant trastuzumab without chemotherapy for treating early HER2-positive breast cancer in older patients: a propensity score-adjusted analysis of a prospective cohort study

enthalten in: ResearchSquare.com | 2022

von Sawaki, M. | Taira, N. | Uemura, Y. | +19

7

Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER) : a randomised, open-label, phase 2 trial

enthalten in: The Lancet. Oncology | 2022

von Saji, S. | Taira, N. | Kitada, M. | +17

CommentIn: Lancet Oncol. 2022 May;23(5):557-558. - PMID 35405086

8

Pertuzumab retreatment for HER2‐positive advanced breast cancer : A randomized, open‐label phase III study (PRECIOUS)

enthalten in: Cancer Science | 2022

von Yamamoto, Y. | Iwata, H. | Taira, N. | +19

9

A phase II study of sequential treatment with anthracycline and taxane followed by eribulin in patients with HER2-negative, locally advanced breast cancer (JBCRG-17)

enthalten in: Breast cancer research and treatment | 2021

von Fukada, I. | Ito, Y. | Kondo, N. | +17

10

Adjuvant Trastuzumab Without Chemotherapy For Treating Early HER2-Positive Breast Cancer In Older Patients: A Cohort Study Accompanying With The RESPECT Trial

enthalten in: ResearchSquare.com | 2021

von Sawaki, M. | Taira, N. | Uemura, Y. | +19

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[11]